If you find this podcast useful please give it a rating and review on iTunes by clicking here
Do you want to get instant company alerts to the front screen of your smartphone? Download the Vox Markets app here: www.VoxMarkets.co.uk/app
On today's Vox Markets Podcast: Cathal Friel, CEO of Open Orphan and Nicola Duke looking at charts
Cathal Friel, Chief Executive Officer of Open Orphan (ORPH) discusses the signing of a preferred partner agreement with the Ipsen Group.
Open Orphan plc is a European-focused, rare and orphan drug consulting services platform. The Company intends to roll up a number of pharma services businesses across Europe. Open Orphan has two data driven digital platforms, a Genomic Health Data Platform, which is establishing one of Europe's largest rare disease genomic database and a Virtual Rep platform enabling pharmaceutical companies to engage key opinion leaders and physicians. The Company is targeting rapid growth in one of the fastest growing sectors in the global pharmaceutical industry targeting under-supplied treatment for life threatening or very serious diseases and rare disorders.
Nicola Duke technical analyst charts:
BitcoinWey Education (WEY)
Xpediator (XPD)
(Interview starts at 9 minutes 1 second)